Soligenix, Inc. (SNGX)
Company Description
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.
It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer.
This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis.
The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19.
The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
| Country | United States |
| IPO Date | Jun 15, 1987 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 13 |
| CEO | Christopher Schaber |
Contact Details
Address: 29 Emmons Dr Ste B10 Princeton, New Jersey 08540-5950 United States | |
| Phone | 609 538 8200 |
| Website | soligenix.com |
Stock Details
| Ticker Symbol | SNGX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 0000812796 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher J. Schaber Ph.D. | Chairman, Chief Executive Officer and Pres |
| Jonathan L. Guarino CPA, CGMA | Senior Vice President, Chief Financial Officer and Corporate Secretary |
| Dr. Oreola Donini Ph.D. | Senior Vice President and Chief Scientific Officer |
| Dr. Richard C. Straube M.D., MSc. | Senior Vice President and Chief Medical Officer |
| Richard L. Dunning | Executive Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
| Mar 29, 2022 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] |
| Jan 21, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jan 21, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jan 4, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Dec 23, 2021 | 8-K | Current report |
| Dec 20, 2021 | 4 | Statement of changes in beneficial ownership of securities |
| Dec 15, 2021 | 25-NSE | Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities |
| Dec 15, 2021 | 4 | Statement of changes in beneficial ownership of securities |
| Dec 15, 2021 | 4 | Statement of changes in beneficial ownership of securities |
| View All SEC Filings | ||